The effectiveness of this massive resale shelf creates immediate and severe overhang. Selling stockholders can now sell into the market at any time, and with the company in a strategic-alternatives process with no active pipeline, the stock faces persistent downward pressure. Traders should expect continued weakness and potential large-block sales. Any strategic alternative announcement (sale, merger, or liquidation) would be the primary catalyst to watch, but the overhang will cap any upside.
Price Chart
Executive Summary
The SEC declared effective Indaptus Therapeutics' S-3 registration (File No. 333-298388) on August 25, 2026, covering up to 58,895,000 shares of common stock for resale by selling stockholders. This effectiveness, combined with a prior S-3 from June 2026 covering 18,864,000 shares, creates a massive potential overhang of up to ~77.8 million shares (~58% of outstanding) that selling stockholders can now sell into the market at any time. The company has no active clinical programs, having discontinued its lead candidate Decoy20, and is evaluating strategic alternatives, making this a significant bearish catalyst for the stock.
Key Facts
- S-3 registration (File No. 333-298388) declared effective on August 25, 2026.
- Registration covers up to 58,895,000 shares of common stock for resale by selling stockholders.
- Combined with a prior June 2026 S-3 covering 18,864,000 shares, total potential overhang is ~77.8 million shares (~58% of outstanding).
- Company has discontinued all clinical development of its lead candidate Decoy20 and has no active programs.
- Auditor has expressed substantial doubt about the company's ability to continue as a going concern.
- Company is evaluating strategic alternatives.
Financial Impact
Potential dilution overhang of up to ~77.8 million shares (~58% of outstanding) from two S-3 resale registrations now effective. No new capital raised for the company.
Risk Factors
- Immediate selling pressure from stockholders who can now resell up to 58.9M shares into the market.
- Combined overhang of ~77.8M shares (~58% of outstanding) from two effective S-3 resale registrations.
- No active clinical programs or revenue to support valuation.
- Going concern risk with substantial doubt from auditor.
- Potential for further dilutive financing if strategic alternatives fail to materialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (INDP) — Batch item 1 | 9999999995-26-002761 |
| Document: 9999999995-26-002761-index.html | 9999999995-26-002761 |
| Document: 9999999995-26-002761.txt | 9999999995-26-002761 |
| EFFECT Filing (INDP) — Batch item 4 | 9999999995-26-002761 |
| Document: 9999999995-26-002761-index.html | 9999999995-26-002761 |
| Document: 9999999995-26-002761.txt | 9999999995-26-002761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access